Purespring Therapeutics Publishes Study on NPHS2 Genetic Variants Driving Adult-Onset FSGS in US and UK Populations

Key Takeaways

• 77% of adult-onset FSGS cases in the US involve compound heterozygosity of NPHS2 variants, particularly R229Q paired with A284V
• A284V variant shows high prevalence in mixed-ancestry populations, highlighting genetic diversity in kidney disease susceptibility
• Research advances precision nephrology approaches for underserved populations with genetic kidney disorders

---

Purespring Therapeutics Identifies Key Genetic Driver of Adult-Onset FSGS

London, April 29, 2026 – Purespring Therapeutics, a precision nephrology company developing targeted genetic therapies for kidney function preservation, announced publication of groundbreaking research identifying an under-recognized genetic driver of adult-onset focal segmental glomerulosclerosis (FSGS) in US and UK populations.

Major Genetic Pattern Discovered

The study reveals that approximately 77% of adult-onset FSGS cases in the United States are predicted to involve compound heterozygosity of two different NPHS2 variants. The most common pairing identified was R229Q with A284V, representing a significant breakthrough in understanding the genetic basis of this kidney disease.

The A284V variant demonstrates particularly high prevalence in mixed-ancestry populations, suggesting important implications for genetic screening and therapeutic development in diverse patient groups.

Clinical Implications for Kidney Disease Treatment

FSGS represents a leading cause of kidney failure requiring dialysis or transplantation. This genetic discovery could transform how clinicians approach diagnosis and treatment selection for adult patients presenting with FSGS symptoms.

“This research advances our understanding of genetic factors driving kidney disease in underserved populations,” the study implications suggest. The identification of specific NPHS2 variant combinations opens new avenues for precision medicine approaches in nephrology.

Market Impact and Future Directions

Purespring’s focus on precision nephrology positions the company at the forefront of genetic kidney disease research. The publication strengthens the scientific foundation for developing targeted therapies addressing specific genetic variants causing kidney dysfunction.

The research particularly emphasizes the importance of genetic diversity considerations in drug development, as the A284V variant’s prevalence in mixed-ancestry populations highlights the need for inclusive therapeutic approaches.

This genetic mapping could accelerate development of personalized treatment protocols and improve outcomes for patients with hereditary forms of kidney disease, representing a significant step forward in precision nephrology.

---

Frequently Asked Questions

What does this genetic discovery mean for FSGS patients?

The identification of specific NPHS2 variants causing 77% of US adult-onset FSGS cases could lead to better genetic screening, earlier diagnosis, and more targeted treatment approaches for patients with this kidney disease.

When will Purespring develop treatments based on this research?

While Purespring hasn’t announced specific timelines, this genetic mapping provides the scientific foundation for developing precision therapies targeting these identified NPHS2 variants in future clinical programs.

How does this compare to current FSGS treatments?

Current FSGS treatments are largely supportive and non-specific. This genetic research could enable precision medicine approaches targeting the underlying genetic causes rather than just managing symptoms.

Related coverage

• Nektar Therapeutics pipeline update: REZPEG, amphotericin B and UK site changes